This article was updated on January 5, 2023.
AmeriHealth HMO, Inc. and AmeriHealth Insurance Company of New Jersey (collectively, AmeriHealth New Jersey), AmeriHealth HMO, Inc. (AmeriHealth Pennsylvania), and AmeriHealth Administrators will make changes to their Select Drug Program® Formulary and Value Formulary.
The changes are effective January 1, 2023, and will include:
Changes in traditional glucose monitoring supplies
- Effective January 1, 2023, OneTouch® products will no longer be the preferred brand test strip/meters on the Select Drug Program and on the Value Formulary.
- On the Select Drug Program, OneTouch® and all non-Contour® test strips will be non-preferred and will require prior authorization.
- On the Value Formulary, OneTouch® and all non-Contour® test strips will be non-formulary.
- Contour® NEXT will be the preferred brand test strip/meters and will not require prior authorization.
- With the changes in preferred test strips, AmeriHealth New Jersey, AmeriHealth Pennsylvania, and AmeriHealth Administrators are offering a free Contour® Next One meter. The new meter can be used with the preferred brand
Contour® test strips.
Changes in continuous glucose monitoring (CGM) supplies
- Effective January 1, 2023, Freestyle Libre® products will no longer be the preferred CGM on the Select Drug Program and on the Value Formulary.
- On the Select Drug Program, Freestyle Libre® will be non-preferred and will require prior authorization.
- On the Value Formulary, Freestyle Libre® will be non-formulary.
- Dexcom® products will be the preferred CGM. Prior authorization continues to be required for Dexcom.
Review the changes that go into effect January 1, 2023:
For more information on pharmacy policies and programs, visit the
AmeriHealth New Jersey,
AmeriHealth Pennsylvania, and
AmeriHealth Administrators websites.